Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Free Report) – Research analysts at Litchfield Hills Research increased their FY2024 EPS estimates for Adial Pharmaceuticals in a note issued to investors on Thursday, November 21st. Litchfield Hills Research analyst T. O’neill now anticipates that the company will earn ($1.31) per share for the year, up from their prior forecast of ($1.82). The consensus estimate for Adial Pharmaceuticals’ current full-year earnings is ($1.53) per share. Litchfield Hills Research also issued estimates for Adial Pharmaceuticals’ Q4 2024 earnings at ($0.37) EPS, Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($1.33) EPS.
ADIL has been the topic of several other research reports. Rodman & Renshaw started coverage on shares of Adial Pharmaceuticals in a report on Thursday, November 14th. They issued a “buy” rating and a $8.00 target price on the stock. RODMAN&RENSHAW upgraded shares of Adial Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, November 14th.
Adial Pharmaceuticals Price Performance
Shares of ADIL opened at $1.00 on Monday. The firm has a 50 day moving average of $1.02 and a 200 day moving average of $1.10. Adial Pharmaceuticals has a twelve month low of $0.77 and a twelve month high of $4.17.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Adial Pharmaceuticals stock. Virtu Financial LLC purchased a new position in shares of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 20,469 shares of the company’s stock, valued at approximately $27,000. Virtu Financial LLC owned about 0.48% of Adial Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 16.41% of the company’s stock.
Adial Pharmaceuticals Company Profile
Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.
Recommended Stories
- Five stocks we like better than Adial Pharmaceuticals
- What Do S&P 500 Stocks Tell Investors About the Market?
- Cerence Up 155% in 2 Days: SoundHound AI’s Fierce Competitor
- The How and Why of Investing in Gold Stocks
- Why Warren Buffett Is Selling: A Look at His Latest Market Moves
- Which Wall Street Analysts are the Most Accurate?
- Why Amazon Shares May Never Trade Below $200 Again
Receive News & Ratings for Adial Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adial Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
